Latest news with #LACC
Yahoo
6 days ago
- Business
- Yahoo
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
Business Wire
6 days ago
- Business
- Business Wire
Personalis' NeXT Personal ® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled 'Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.' The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. 'Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer,' said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. 'We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer,' said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. 'Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients.' About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO.
USA Today
28-04-2025
- Sport
- USA Today
Future U.S. Women's Open venues include seven clubs hosting championship for first time
Future U.S. Women's Open venues include seven clubs hosting championship for first time The countdown is on for the U.S. Women's Open in 2025. This year marks the 80th women's national championship, and Erin Hills Golf Course in Erin, Wisconsin, will be the host venue for the landmark event. The USWO will be the second of five majors for the LPGA in 2025. In all, the U.S. Golf Association has announced 18 future U.S. Women's Open locations through 2048, although there are several years with locations still to be announced (2037, 2039, 2041, 2043, 2044, 2047). Among the many list below are seven historic clubs that are slated to host the women for the first time, including this year and next. Check out this list of future stops, which includes the first trip to Riviera in the very near future. 2025 Erin Hills, Erin, Wisconsin Site of the 2017 U.S. Open victory of Brooks Koepka, Erin Hills will host the women's Open for the first time this year. 2026 Riviera Country Club, Pacific Palisades, California The Riv is hosting the women for the first time in 2026 and the men's and women's Olympics in 2028. 2027 Inverness Club, Toledo, Ohio Inverness has hosted two previous USWO's: Susie Berning (1973) and Jane Geddes (1986). It also hosted the 2021 Solheim Cup, won by Europe. 2028, 2038 Oakmont Country Club, Oakmont, Pennsylvania Patty Sheehan (1992) and Paula Creamer (2010) won the two previous U.S. Women's Opens there. Oakmont, hosting the men's U.S. Open in 2025, has two future USWOs on tap. 2029 Pinehurst Resort & Country Club, Pinehurst, North Carolina Michelle Wie West won the USWO at Pienhurst No. 2 in 2014 when the course hosted the men and the women back-to-back. In 2029, the consecutive Opens will be played again at Pinehurst. 2030 Interlachen Country Club, Edina, Minnesota The 2030 U.S. Women's Open will be the second played at Interlachen (a 19-year-old Inbee Park won it in 2008) and it's scheduld to be played on the 100th anniversary of Bob Jones' U.S. Open victory at Interlachen his third straight major win en route to the grand slam. 2031, 2042 Oakland Hills Country Club, Bloomfield Township, Michigan This will be the first U.S. Women's Open at Oakland Hills, which has hosted 12 previous USGA championships. It will become the fifth club to have hosted a U.S. Open, U.S. Women's Open, U.S. Amateur and U.S. Women's Amateur. 2032 Los Angeles Country Club LACC hosted the men's U.S. Open in 2023 and in 2032 it will host the women for the first time. LACC hosted the U.S. Women's Amateur in 1930. 2033 Chicago Golf Club, Wheaton, Illinois This will be the first time the U.S. Women's Open will be held at Chicago Golf Club, one of the five founding clubs of the USGA. The club hosted the inaugural U.S. Senior Women'''s Open in 2018, won by Laura Davies 2034, 2046 Merion Golf Club, Ardmore, Pennsylvania As of 2023, Merion has hosted more USGA championships than any other venue but in 2034, the U.S. Women's Open will be staged there for the first time. 2035, 2040, 2048 Pebble Beach Golf Links, Pebble Beach, California Pebble hosted the USWO for the first time in 2023 and will do so again 12 years later and then again five years after that. 2036 Shinnecock Hills Golf Club, Southampton, New York This will be the first U.S. Women's Open at Shinnecock. It'll also be a part of a back-to-back for the club, which will host the men and the women on consecutive weeks in 2036. 2045 The Country Club, Brookline, Massachusetts
Yahoo
13-02-2025
- Politics
- Yahoo
Liberian president suspends hundreds of officials over asset declaration failure
Liberian President Joseph Boakai has suspended more than 450 top government officials, including ministers, for failing to declare their assets to the anti-corruption agency. They will be off work without pay for a month or "until they submit the required declarations", according to the presidency. Boakai said that the officials had contravened the code of conduct for state officials by not being transparent about what they own. The president, who had pledged to fight corruption when he came into office last year, said failure to comply undermined efforts to combat corruption and ensure accountability. Among those suspended include the ministers for education and health, as well as the special envoys for tourism and investment. They also include officials working for the Executive Mansion, the official residence of the president, and county administrative officials. The law requires all public officers to declare their wealth before taking up their posts and when they leave positions in government. The Liberia Anti-Corruption Commission (LACC) published the list of all the 457 affected public officials, noting it was doing so as prescribed by law. Boakai, who pledged to fight corruption when he came into office last year, said failure to comply undermined efforts to combat corruption and ensure accountability. Who is Liberian President Joseph Boakai? "Public officials are reminded that asset declaration is not only a legal obligation but also a fundamental measure to promote transparency and restore public trust in governmental institution," he said in a statement. Last July, the president announced that he was reducing his salary by 40%, saying he hoped to set a precedent for "responsible governance" and demonstrate "solidarity" with Liberians. The government of his predecessor, George Weah, had faced accusations of corruption and lavish spending, sparking mass protests amid a rise in the cost of living. On Wednesday, some of the suspended officials visited the anti-corruption commission offices in order to comply with the requirement. There has been mixed reaction over the president's move. Political analyst Abdullah Kiatamba was quoted by Liberian newspaper FrontPage Africa as being supportive of the president's anti-corruption stance, but raised concerns about the challenges some officials faced in submitting their asset declarations. Civil society group Solidarity and Trust for a New Day described Boakai's move as insufficient. "Suspending these officials for just one month is a meaningless, symbolic gesture - a slap on the wrist that no serious person should take seriously," it said in a statement. Go to for more news from the African continent. Follow us on Twitter @BBCAfrica, on Facebook at BBC Africa or on Instagram at bbcafrica Africa Daily Focus on Africa
BBC News
13-02-2025
- Politics
- BBC News
Liberia anti-corruption: President Boakai suspends top officials for non-declaration of assets
Liberian President Joseph Boakai has suspended more than 450 top government officials, including ministers, for failing to declare their assets to the anti-corruption will be off work without pay for a month or "until they submit the required declarations", according to the said that the officials had contravened the code of conduct for state officials by not being transparent about what they president, who had pledged to fight corruption when he came into office last year, said failure to comply undermined efforts to combat corruption and ensure accountability. Among those suspended include the ministers for education and health, as well as the special envoys for tourism and also include officials working for the Executive Mansion, the official residence of the president, and county administrative law requires all public officers to declare their wealth before taking up their posts and when they leave positions in Liberia Anti-Corruption Commission (LACC) published the list of all the 457 affected public officials, noting it was doing so as prescribed by who pledged to fight corruption when he came into office last year, said failure to comply undermined efforts to combat corruption and ensure is Liberian President Joseph Boakai?"Public officials are reminded that asset declaration is not only a legal obligation but also a fundamental measure to promote transparency and restore public trust in governmental institution," he said in a July, the president announced that he was reducing his salary by 40%, saying he hoped to set a precedent for "responsible governance" and demonstrate "solidarity" with government of his predecessor, George Weah, had faced accusations of corruption and lavish spending, sparking mass protests amid a rise in the cost of Wednesday, some of the suspended officials visited the anti-corruption commission offices in order to comply with the has been mixed reaction over the president's move. Political analyst Abdullah Kiatamba was quoted by Liberian newspaper FrontPage Africa as being supportive of the president's anti-corruption stance, but raised concerns about the challenges some officials faced in submitting their asset society group Solidarity and Trust for a New Day described Boakai's move as insufficient."Suspending these officials for just one month is a meaningless, symbolic gesture - a slap on the wrist that no serious person should take seriously," it said in a statement. Go to for more news from the African us on Twitter @BBCAfrica, on Facebook at BBC Africa or on Instagram at bbcafrica
